abiraterone

Update on the Combination Use of Zytiga and Xofigo

Sub-group analysis of the clinical trial ERA 223 signal that the concerns about the use in combination of Zytiga and Xofigo might not cause a significant increase in the risk for developing bone fractures if a man is also simultaneously on a bone targeted therapy.

Statin Use Along with Zytiga or Xtandi Extends Survival in Men Who Failed Chemotherapy 

Statins have been in the prostate cancer news feeds for a long time.  They are believed to potentiate the effects of the anti-hormonal agents used to treat metastatic castration-resistant prostate cancer (mCRPC). Different stages of prostate cancer as well as different treatment exposures might change the efficacy of statins. 

Comparing the Efficacy of the Treatment Options of Metastatic, Castration-Resistant, Docetaxel-Resistant Prostate Cancer

There was a large meta-analysis recently published that compared the efficacy of abiraterone acetate (Zytiga), enzalutamide (Xtandi), cabazitaxel (Jevtana) and Radium-223 (Xofigo) in the treatment of castration-resistant, docetaxel-resistant metastatic prostate cancer.